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Edited by Vladimir SkulachevAbstract HGTD-P is a hypoxia-responsive pro-apoptotic
protein that transmits hypoxic signals directly to mitochondria.
When overexpressed, HGTD-P induces cell death via typical
mitochondrial apoptotic cascades. However, much is unknown
about post-transcriptional modiﬁcation and signaling networks
of HGTD-P in association with cell death-regulating proteins.
We performed yeast two-hybrid screening to identify the mole-
cules involved in HGTD-P-mediated cell death pathways. In this
study, we show that heat shock protein 90 physically interacts
with HGTD-P and that suppression of Hsp90 activity by low
concentrations of geldanamycin reduced HGTD-P-induced mito-
chondrial catastrophe through inhibition of mitochondrial trans-
location of HGTD-P.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Mitochondria1. Introduction
Heat shock proteins (Hsps) are ubiquitous, highly expressed
proteins involved in the defense mechanisms against cellular
damage. They can be grouped into various families according
to their molecular weights: namely the 110-, 90-, 70-, 60-, 40-
kDa and low molecular weight families [1]. The 90-kDa heat
shock protein (Hsp90) is a molecular chaperone required by
a number of signaling proteins for facilitating the proper con-
formation, stabilization, and localization of its client proteins
[2–4].
Conformational change and translocation of pro-apoptotic
molecules onto mitochondria are important processes in exe-
cuting the cell death program. Bax, for example, undergoes a
conformational modiﬁcation that leads to exposure of both
its amino (N)- and carboxy (C)-terminal ends, which results
in translocation of Bax from cytosol to mitochondria [5–7],Abbreviations: 17-AAG, 17-(Allylamino)-17-demethoxygeldanamycin;
DAPI, 4 0,60-diamidino-2-phenylindole; GA, geldanamycin; HIF-1a,
hypoxia-inducible factor-1a; Hsp, heat shock protein; MMP, mito-
chondrial membrane potential
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doi:10.1016/j.febslet.2006.05.001subsequent release of cytochrome c [8], and activation of casp-
ases through the formation of apoptosomes [9].
HGTD-P is a pro-apoptotic eﬀecter molecule of hypoxia-
inducible factor 1a (HIF-1a) that directly links the compli-
cated cell death signals activated by hypoxia to mitochondria
[10]. When overexpressed, mitochondria-targeted HGTD-P
triggers typical mitochondrial apoptotic cascades, including
dissipation of mitochondrial membrane potential (MMP)
and activation of caspase-9 [10]. However, much is unknown
about post-transcriptional modiﬁcation and signaling net-
works of HGTD-P in association with cell death-regulating
proteins.
The purpose of this work was to identify and characterize
the molecules and their molecular mechanisms involved in
HGTD-P-mediated cell death pathways. We carried out yeast
two-hybrid screening and immunoprecipitation to ﬁnd
HGTD-P-binding protein and show in this report that
Hsp90 is required for mitochondrial targeting of HGTD-P
and induction of mitochondrial apoptotic cascades.2. Materials and methods
2.1. Reagents, cell culture, and cell death assay
The human A549 alveolar epithelial cell line was obtained from the
American Type Culture Collection (Rockville, MD) and cultured in
RPMI 1640 medium (Gibco BRL, CA) containing 10% fetal bovine
serum under 5% CO2 at 37 C. Apoptotic cells exhibiting altered nucle-
ar morphology following 4 0,6 0-diamidino-2-phenylindole (DAPI)
staining were enumerated manually under a ﬂuorescence microscope.
Geldanamycin (GA) and 17-(Allylamino)-17-demethoxygeldanamycin
(17-AAG) were purchased from Calbiochem (San Diego, CA). Anti-
V5 antibody were purchased from Invitrogen Corp. (Carlsbad, CA),
and anti-Hsp90, -Hsp60, and -b-actin antibodies were obtained from
Abcam (Cambridge, UK). Anti-HGTD-P antibody was produced by
immunizing a rabbit with keyhole limpet hemocyanin-conjugated
amino acid residues 33–48 (DLKRINGFCTKPQESP) of HGTD-P.
Antibody was puriﬁed from the immune serum by aﬃnity chromatog-
raphy. All other reagents were purchased from Sigma–Aldrich Inc. (St.
Louis, MO), unless otherwise speciﬁed.
2.2. Yeast two-hybrid screening
HGTD-P, a bait protein, is expressed as a fusion with the GAL4
DNA-binding domain (DNA-BD) in yeast strain AH109 and the
cDNA library is expressed as a fusion to the GAL4 activation domain
(AD) in yeast strain Y187 (Clontech Laboratories Inc., CA). The two
yeast strains were mixed and incubated overnight in 2· YPDA/Kan
medium, which were allowed to grow at 30 C. Transformant cells
were then plated on selection medium SD/-Ade/-His/-Leu/-Trp to select
for colonies strongly expressing both the ADE2 and HIS3 reporters.
Also, the plates were added X-a-Gal for the colorimetric detection of
the MEL1 reporter gene product, a-galactosidase.blished by Elsevier B.V. All rights reserved.
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DNAs encoding HGTD-P (Accession No. AF201944) was ampliﬁed
by polymerase chain reaction (PCR) from a human kidney cDNA li-
brary and cloned into the pcDNA3.1/V5 (Invitrogen Corp.). A549 cells
(3 · 105/10 cm culture dish) were transiently transfected with 2 lg of
plasmid using Transfast Reagent (Promega, CA) and harvested at
the indicated time points.
2.4. Cell fractionation, immunoprecipitation and immunoblotting
Cell fractionation was performed as described previously [11]. Solu-
bilized cellular extracts in lysis buﬀer were pre-cleared to discard non-
speciﬁc bindings and the resultant supernatants were incubated with
primary antibody (3 lg) at 4 C. Immunoprecipitates were collected
by incubation with protein G-Sepharose for 1 h, followed by centrifu-
gation at 4 C. After being washed three times, the immunoprecipitates
and immunodepleted ﬁnal supernatants were subjected to Western
blotting, as described previously [10].
2.5. Geldanamycin treatment
For pre-treatment withGA, cells were incubatedwith 0.5 or 5 lMGA
3 h prior to transfection and maintained in culture medium containing
the same concentration of GA for the indicated time periods. For co-
treatment of GA, cells were treated with 0.5 or 5 lMGA at the time of
transfection andmaintained in culturemediumcontaining the same con-
centration of GA for the indicated time periods. For post-treatment of
GA, cells were treated with 0.5 or 5 lMGA after 12 h of transfection.
2.6. Determination of MMP, immunocytochemistry, and caspase
colorimetric assay
Determination of MMP by ﬂow cytometry and immunocytochemis-
try were as described previously [10]. Caspase-3 and -9 activities were
measured using the colorimetric caspase-3 (Peptron, Korea) and cas-
pase-9 (Biosource, CA) assay kits, respectively, according to the man-
ufacturer’s instructions.Fig. 1. Interaction of HGTD-P with Hsp90. Cells were transiently
transfected with 2 lg of HGTD-P expression vector (pcDNA-HGTD-
P) tagged with V5. After 48 h of transfection, cells were harvested and
immunoprecipitated using anti-V5 antibody. The immunoprecipitated
pellet and immunodepleted ﬁnal supernatant were subjected to
Western blotting with anti-Hsp90 antibody (upper panels). Expression
of each protein was veriﬁed by immunoblotting using cell lysates with
which immunoprecipitation was performed (lower panels). Represen-
tative immunoblots are shown.3. Results
3.1. HGTD-P physically interacts with Hsp90
In an attempt to identify the signaling molecules involved in
HGTD-P-mediated cell death, the full length of HGTD-P was
used as bait for yeast two-hybrid screening with a human brain
cDNA library. Among the 3 · 106 yeast transformants, 12
clones were found to be true interacting positives on selection
medium SD/-Ade/-His/-Leu/-Trp and a-gal plate only when
they were co-expressed with Gal4–HGTD-P fusion protein.
Positive two-hybrid protein interactions were veriﬁed by trans-
fection of the plasmids back into the host together with the ori-
ginal bait or with selected controls. DNA sequence analysis of
the plasmid insert and computer-assisted database search re-
vealed that the nucleotide sequence of three clones encoded
Hsp90 (Accession No. M16660). In order to demonstrate that
HGTD-P interacts with Hsp90 in mammalian cells, HGTD-P
was overexpressed in A549 cells by transfection using
pcDNA3.1 vectors coding for V5-tagged HGTD-P (HGTD-
P-V5). HGTD-P was immunoprecipitated using anti-V5
antibody and the immunoprecipitates were blotted with an
anti-Hsp90 antibody. Hsp90 was detected in V5 immunopre-
cipitates (Fig. 1, upper panel). Expression of transfected plas-
mid or Hsp90 was conﬁrmed by Western blots of cell lysate
used for immunoprecipitation (Fig. 1, lower panel).
3.2. Inhibition of Hsp90 activity protects cells against HGTD-P
overexpression
To gain insight into the signiﬁcance of physical interaction
with Hsp90, we initially determined whether the inhibition ofHsp90 aﬀects the pro-apoptotic activity of HGTD-P. Cells
were pre-treated with Hsp90 inhibitor GA at high (5 lM) or
low (0.5 lM) concentration and transiently transfected with
2 lg of pcDNA-HGTD-P. Apoptotic cells with a condensed
chromatin pattern among HGTD-P-transfected cells were
counted for the diﬀerent time intervals. As shown in Fig. 2A,
a high concentration of GA did not signiﬁcantly aﬀect cell
death rate induced by HGTD-P overexpression. Interestingly,
the low concentration of GA suppressed HGTD-P-induced
cell death to 14% as compared with 45% in GA-untreated cells
(Fig. 2B). In parallel, caspase-3 activity was suppressed by the
lower concentration of GA (Fig. 2C), but not by the high con-
centration of GA (data not shown). Next, to explore the con-
centration-dependent eﬀects of GA on HGTD-P-induced
apoptosis, cells were pre-treated with varying concentrations
of GA and transfected with 2 lg of pcDNA-HGTD-P. Follow-
ing 48 h of transfection, cell death was determined as described
above. As shown in Fig. 2D, GA suppressed HGTD-P-in-
duced cell death at the low concentration, but not at the high
concentration over 2 lM. In order to conﬁrm the results ob-
tained from GA treatment, cells were further treated with
hsp90 inhibitors 17-AAG and radicicol. Both 17-AAG and
radicicol also suppressed cell death induced by HGTD-P over-
expression (Fig. 2E). Our data suggest that Hsp90 is required
for the death-promoting activity of HGTD-P.
3.3. Hsp90 regulates pro-apoptotic activity of HGTD-P
upstream of mitochondria
Previously, we showed that HGTD-P induced apoptosis via
mitochondrial cascades such as loss of MMP and activation of
caspase-9 [10]. After observing the inhibition of HGTD-P-
mediated cell death by GA, we wanted to address whether
GA inhibited HGTD-P-mediated cell death upstream or
downstream of mitochondria. Cells were treated with 0.5 lM
GA before or after transfection with 2 lg of pcDNA-
HGTD-P. After 24 h of transfection, a cell death assay was
Fig. 2. Eﬀects of Hsp90 inhibitors on cell death induced by HGTD-P overexpression. Cells were treated or untreated with 5 (A) or 0.5 lM (B) GA
for 3 h, and then transfected with mock or 2 lg of pcDNA-HGTD-P. After indicated time points, cells were stained with DAPI and apoptotic cells
were counted under a ﬂuorescent microscope. (C) Cells were treated with 0.5 lMGA for 3 h, followed by transfection with mock or 2 lg of pcDNA-
HGTD-P. After indicated time points, cells were harvested and relative caspase-3 activity was determined. Fold increases of caspase activities to
mock transfection (arbitrarily deﬁned as 1) are presented. (D) Cells were untreated or treated with the indicated concentration of GA for 3 h, and
then transfected with mock or 2 lg of pcDNA-HGTD-P. Cell death rate was determined as in A after 48 h of transfection. (E) Cells were pre-treated
with 600 nM radicicol or 800 nM 17-AAG for 12 h and then transfected with 2 lg of pcDNA-HGTD-P or control vector. Following 48 h of
transfection, dead cells were counted as above. The means ± S.D. of three independent experiments is shown.
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treatment with GA rescued cells from HGTD-P overexpres-
sion while co-treatment or post-treatment with GA did not sig-
niﬁcantly reduce cell death, suggesting that Hsp90 acts in early
stages of the HGTD-P-mediated cell death pathway. Next, we
examined whether the dissipation of MMP induced by HGTD-
P overexpression was overcome by GA. Following 24 h of
transfection, MMP was determined by ﬂow cytometry after
staining with MitoTracker Red in GA-treated cells. As shown
in Fig. 3B, GA pre-treatment suppressed the loss of MMP
while co-treatment or post-treatment failed to inhibit dissipa-
tion of MMP. In line with alteration of mitochondrial param-
eter, caspase-9 activity was detected in GA co- or post-treated
cells, but not in pre-treated cells (Fig. 3C). Taken together, our
data imply that the eﬀect of Hsp90 on HGTD-P-mediated cell
death is upstream of mitochondrial events.3.4. Hsp90 is required to target HGTD-P to mitochondria
We next wanted to address the mechanism by which Hsp90
modulates HGTD-P-induced cell death upstream of mitochon-
dria. To this end, cells were pre-treated with GA and then
transfected with 2 lg of pcDNA-HGTD-P/V5, or transfected
with co- or post-treatment of GA. After 18 h of transfection,
cells were double stained using anti-V5 antibody for HGTD-
P and anti-Hsp60 antibody for a mitochondrial marker [12].
Consistent with previous reports [10], HGTD-P was com-
pletely overlayed with Hsp60 in GA-untreated control cells.However, diﬀerent co-localization patterns according to GA
treatment time were noted. Pre-treatment of GA displaced
overexpressed HGTD-P to non-mitochondrial sites while
co- or post-treatment did not change the mitochondrial localiza-
tion of HGTD-P (Fig. 4A). To conﬁrm our immunocytochem-
ical results, immunoblots following cell fractionation were
performed. As shown in upper panel of Fig. 4B, HGTD-P
was detected mainly in the heavy membrane fraction (HM)
in GA-untreated control cells. However, pre-treatment of
GA displaced HGTD-P to the light membrane or cytosolic
compartment. In contrast, co- or post-treatment of GA mini-
mally aﬀected compartmental displacement of HGTD-P.
Proper cellular fractionation was conﬁrmed by Western blot
for Hsp60 (Fig. 4B, lower panel). These results suggest that
Hsp90 is required for pro-apoptotic activity of HGTD-P by
regulating mitochondrial translocation of HGTD-P.3.5. Treatment with GA increases proteasomal degradation of
HGTD-P
The stability of a large number of proteins that are degraded
by the ubiquitin-proteasome pathway is determined by assem-
bly of heterocomplexes with hsp90 [13]. Therefore, we tried to
determine the change of half-life of HGTD-P in cells treated
with GA or not treated. Cells were pre-treated with 0.5 lM
GA or vehicle control 6 h before adding 20 lg/ml translation
inhibitor cycloheximide. At the indicated time points, cells
were harvested and HGTD-P expression level was estimated
Fig. 3. Regulation of HGD-P pro-apoptotic activity by Hsp90 is
upstream of mitochondria. Cells were untreated, pre-treated, co-
treated, or post-treated with 0.5 lM GA before or after transfection
with 2 lg of pcDNA-HGTD-P or control vector, as described in
Section 2. (A) After 24 h of transfection, cells were stained with DAPI
and apoptotic cells were counted under a ﬂuorescent microscope. The
means ± S.D. of three independent experiments is shown. (B) Follow-
ing 24 h of transfection, MMP was determined using MitoTracker Red
by ﬂow cytometry. (C) Cells were harvested at the indicated time
points following transfection with 2 lg pcDNA-HGTD-P/V5 and
caspase-9 activity was determined. Fold increases of caspase-9 activ-
ities to mock transfection (0 h) were presented. The means ± S.D. of
three independent experiments is shown.
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promoted the destabilization of HGTD-P and the decrease
of HGTD-P expression was attenuated by simultaneousexposure to proteasomal inhibitor lactacystin. These results
suggest that HGTD-P is stabilized by hsp90 and degraded by
the ubiquitin-proteasome pathway like other client proteins
when hsp90 heterocomplex assembly is inhibited.4. Discussion
Hsp90 is a highly conserved, ubiquitous protein involved in
maintaining appropriate folding and conformation of its client
proteins and regulating compartmental transport of proteins
inside cells [14–16]. Initially we have shown that hypoxia-
responsive pro-apoptotic protein HGTD-P interacts with
Hsp90 using yeast two-hybrid screening and immunoprecipita-
tion. Over 50 proteins have been identiﬁed as clients of Hsp90
[17] and a great many Hsp90 client proteins, including Akt,
Her2, and HIF-1a, are involved in cytoprotection against dif-
ferent types of cellular stresses [18–22]. However, our results
are somewhat surprising, given that the interaction of Hsp90
with HGTD-P accelerated cell death. To date, it has been re-
ported that Hsp90 leads to increased apoptosis following tu-
mor necrosis factor-a induction [23]. Together with our data,
it suggests that Hsp90-associated meshwork may regulate both
cell survival and death pathways.
Next, we showed that the inhibition of Hsp90 activity by a
low concentration of GA or its derivatives rescued cells against
HGTD-P overexpression while a high concentration of GA
failed to inhibit cell death irrespective of HGTD-P expression
level. Furthermore, GA itself induced cell death at a high level
of concentration, consistent with previous reports [24] and di-
rect cytotoxicity at the high concentration may account for
synergistic increase of cell death in HGTD-P overexpressed
cells. These bimodal eﬀects of GA suggest that there are, at
least, two diﬀerent action mechanisms in the suppression of
Hsp90, depending on GA concentration. In accordance with
this, recently, the diﬀerential eﬀects of GA on hsp90 client pro-
tein HIF-1a and its target gene expression according to con-
centration range have been reported [25]. Although the
precise biochemical mechanism of the dosage-dependent bimo-
dal eﬀects of GA on Hsp90 function is not clear, it may result
from the enhanced formation of hydrogen peroxide or super-
oxide by high concentration of GA [26,27]. Increased oxygen
radicals caused by high GA treatment may aﬀect the function
of a variety of proteins including Hsp90 or the regulations of
the gene expression.
Given the role of Hsp90 in HGTD-P-induced cell death, our
next concern was how Hsp90 modulated the function of
HGTD-P protein. Hsp90 seems to act at an early stage of cell
death induced by HGTD-P overexpression, as evidenced by
the observation that cell viability of GA pre-treated cells was
maintained against HGTD-P overexpression, whereas co- or
post-treatment of GA after transfection did not reduce or only
slightly reduced cell death. This ﬁnding suggests that Hsp90
may interact with HGTD-P before the initiation of the mito-
chondrial apoptotic cascades. In an attempt to identify the
events occurring at the early stage of Hsp90–HGTD-P interac-
tion, we determined the mitochondrial parameters of cell in-
jury. Our data clearly showed that the suppression of Hsp90
by GA inhibited loss of MMP and resultant caspase-9 activa-
tion in Hsp90-suppressed cells prior to HGTD-P transfection.
We previously showed that mitochondrial outer membrane
targeting of HGTD-P is essential for pro-apoptotic activity
Fig. 4. Eﬀects of Hsp90 on mitochondrial translocation of HGTD-P. (A) Cells were untreated, pre-treated, co-treated, or post-treated with 0.5 lM
GA for 3 h before or after transfection with 2 lg of pcDNA-HGTD-P/V5 or control vector, as in Fig. 3. After 18 h of transfection, cells were double
stained with anti-V5 (green ﬂuorescence) and anti-Hsp60 (red ﬂuorescence) antibodies, and visualized using a confocal microscope. (B) Cells were
treated as above and immunoblots were done after cell fractionation using anti-V5 antibody for HGTD-P (upper panel) or Hsp60 (lower panel).
Representative blot is shown. HM, heavy membrane fraction; LM, light membrane fraction; Cy, cytoplasmic fraction; Lysate, whole cell lysate.
Fig. 5. Hsp90 regulates turnover of HGTD-P. Cells were treated with
(+) or without () 0.5 lM GA or 10 lM lactacystin (LC) for 6 h, and
then treated with 20 lg/ml cycloheximide for the indicated time. After
incubation, cells were harvested, lysated, and subjected for immuno-
blot for HGTD-P, Hsp90 and b-actin. Representative blot of three
experiments is shown.
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intervene at nearly every step in the apoptotic pathway by reg-
ulating protein–protein interaction or protein traﬃcking.
Therefore, the results obtained from mitochondrial parameters
suggest the possibility that Hsp90 participates in the mitochon-
drial targeting process of HGTD-P. Our data from co-localiza-
tion and cell fractionation studies support this possibility that
Hsp90 activity is required for mitochondrial translocation of
HGTD-P. Although ATP hydrolysis by intrinsic ATPase
activity is critical for the conformational change and transloca-
tion of the most of its client proteins [28], it remains to be elu-
cidated in case of HGTD-P.
Treatment of Hsp90 inhibitors is known to stimulate the
proteasome-dependent degradation of several Hsp90 client
proteins [29]. In addition to translocating HGTD-P to mito-
chondria, Hsp90 participates in stabilization of HGTD-P be-
cause treatment of GA caused rapid destabilization ofHGTD-P. The degradation of proteins that fail to fold cor-
rectly is frequently regulated by proteasome. Our results de-
picted in Fig. 5 also show that the proteasome pathway is
indeed involved in HGTD-P degradation, evidenced by the
use of the proteasome inhibitor lactacystin.
In conclusion, we identiﬁed hypoxia-responsive protein
HGTD-P as a new member of Hsp90-binding molecules and
showed that Hsp90 was essential for the pro-apoptotic activity
of HGTD-P by translocating HGTD-P to mitochondria.
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